Research Article
Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson’s Disease
Table 1
Cox proportional hazard ratios estimating the risk for motor complications with respect to genotypes in functional polymorphisms associated with lower enzyme/transporter activitya.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HR: hazard ratio; 95% CI: 95% confidence interval. aPatients were grouped into low/intermediate enzyme/transporter activity (DDCCC/CT (n = 23); MAOBCC/(C)/CT (n = 16); COMTAA/AG (n = 23); DAT≤9/≤10 (n = 13)) and high enzyme/transporter activity (DDCTT (n = 7); MAOBTT/(T) (n = 14); COMTGG (n = 7); DAT10/10 (n = 17)). Refer to Supplementary Table S1 for details. bAn HR < 1 indicates smaller risk for motor complications with genotypes resulting in low/intermediate enzyme/transporter activity (DDCCC/CT rs921451 genotype; MAOBCC/(C)/CT rs1799836 genotype; COMTAA/AG rs4680 genotype; DAT≤9/≤10 V NTR genotype). cAdjustment of HR for relevant covariates was performed by using multivariate Cox proportional hazard models using a stepwise selection process retaining as final variables disease duration at baseline for the prediction of wearing-off, gender, disease duration at baseline, and MAOB-I therapy for levodopa-induced dyskinesia and no variables for any motor complication (no adjustment needed). |